News

March 11, 2019
Espero BioPharma Announces Tecarfarin Receives FDA Orphan Drug Designation for Patients with End Stage Renal Disease and Atrial Fibrillation
​​
January 24, 2019
Espero BioPharma Provides Update on the Development of Tecarfarin for the Treatment of Mechanical Heart Valve Patients in China

October 9, 2018
Espero BioPharma Appoints Lee Golden, M.D., as Chief Medical Officer

August 29, 2018
Lee Pharmaceutical : VOLUNTARY ANNOUNCEMENT - UPDATE ON THE INTRODUCTION AND RESEARCH AND DEVELOPMENT OF AN INVESTIGATIONAL ANTICOAGULANT

July 17, 2018
Sinovant Sciences and Renexxion Form Partnership to ​Develop Naronapride in China

February 28, 2018
​Exclusive: Jacksonville's fastest-growing company commits to stay, eyes public offering

Dec. 12, 2017
​Espero BioPharma Provides Corporate Update and 2018 Objectives
​​
30 March, 2017
Espero Pharmaceuticals and Armetheon to Merge and Create A Premier Cardiovascular Focused Biopharmaceutical Company 

14 February, 2017
Armetheon Announces European Medicines Agency's Support for 1000 Patient Single Phase 3 Study Prior to MAA Filing for its Novel Oral Anticoagulant Tecarfarin

13 February, 2017
Armetheon Announces Issuance of a New U.S. Patent for its Phase 2 Clinical Stage Novel Oral Antiarrhythmic Budiodarone 

9 February, 2017
Armetheon Reaches Agreement with FDA to Conduct a 1000 Patient Single Phase 3 Study Prior to NDA Filing for its Novel Oral Anticoagulant Tecarfarin
​
17 November, 2016
Bioworld: Renexxion advances former Aryx GI drug under new FDA guidance

16 November, 2016
Renexxion Achieves Positive FDA Guidance for Phase 3 ready GI Drug Naronapride

25 August 2016
Armetheon Announces Positive Results of Pharmacokinetics Study of Tecarfarin versus Warfarin

23 August, 2016
Armetheon Announces Positive Tecarfarin Clinical Data to be Presented at the European Society of Cardiology (ESC) Congress 

26 May, 2016
Armetheon Completes Acquisition of Budiodarone and Plans Development for the Treatment of Ventricular Tachycardia in Patients with Implantable Cardioverter Defribilators

14 October, 2015
Armetheon to Present at the 14th Annual Bio Investor Forum  

8 October, 2015
Armetheon to Participate in the Hume Brophy 7th Annual Healthcare Conference  

22 September, 2015
Armetheon and Lee's Pharma Enter into Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand 

8 September, 2015
Armetheon to Present at the 22nd Annual Newsmakers in the Biotech Industry Conference 

18 August, 2015
Armetheon Expands Leadership Team, Names Detlef Albrecht, M.D., as Chief Medical Officer

3 June, 2015
Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer

8 May, 2015
Armetheon, Inc. Announces Appointment of Andrew C. Lam as Vice President of Product Development

9 March, 2015
WSJ Venture Investment in Heart Therapies Rebounds by Brian Gormley


28 February, 2018
Exclusive: Jacksonville's fastest-growing company commits to stay, eyes public offering

17 February, 2015
Armetheon, Inc. Appoints John F. Glenn as Chief Financial Officer

5 February, 2015
Armetheon Closes $24 Million Series B Financing

5 February, 2015
FierceBiotech  Armetheon Raises $24M To Get Its Anticoagulant Into Phase III by Damian Garde 

5 February, 2015
Dow Jones Armetheon Raises $24M Series B Round, Prepares for Phase III Anticoagulant Trials by Brian Gormley

28 August, 2014
Armetheon Completes $7.0 Million Series A Financing

29 April, 2014
Armetheon Announces FDA Agreement on SPA for Potential Best in Class
Oral Anticoagulant for All Patients, including those with Prosthetic Heart Valves.

15 April, 2013
BioWorld Today (Vol. 24, No. 71):  Armetheon Seeks to Repurpose Stalled Late-Stage Compounds  by Marie Powers

8 March, 2013
PR Newsire:   A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction

11 June, 2012
BioCentury: The Bernstein Report on BioBusiness Emerging Companies: Armetheon: Stopping the Bleeding by Jon Wolleben

9 February, 2012
DOWJONES: VentureWire Altheos Ups Series A To $32.5M, Begins Clinical Trials Of Glaucoma Eye Drop by Brian Gormley

9 February, 2012
FierceBiotech Altheos grabs $12.5M more, launches glaucoma trial by Mark Hollmer

9 February, 2012
Altheos Announces Initiation of Phase 2a Clinical Trial for its Lead Glaucoma Drug Candidate, ATS907

30 September, 2010
Altheos Names Barbara Wirostko, M.D., Chief Medical Officer

13 April, 2010
DOWJONES: VentureWire LifeScience Atheneos Capital Takes Hands-On Approach With Its Debut Angel Fund by Jonathan Matsey

12 April, 2010
BioCentury: Strategy Altheos mines its Rho-lodex by Aaron Bouchie

6 April, 2010
BioWorld Today Altheos Raises $20M; Gets into Glaucoma ROCK Inhibitor Game by Trista Morrison

5 April, 2010
Altheos Completes $20 Million Series A Financing to Develop Next-Generation Glaucoma Treatment

This part of our website contains archival information which should not be considered current and may no longer be considered accurate.

“There is nothing impossible to him who will try.” - Alexander the Great